JPH11500614A - 多重腫瘍異常生長遺伝子 - Google Patents
多重腫瘍異常生長遺伝子Info
- Publication number
- JPH11500614A JPH11500614A JP8524678A JP52467896A JPH11500614A JP H11500614 A JPH11500614 A JP H11500614A JP 8524678 A JP8524678 A JP 8524678A JP 52467896 A JP52467896 A JP 52467896A JP H11500614 A JPH11500614 A JP H11500614A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- chromosome
- cells
- mag
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 191
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 158
- 230000012010 growth Effects 0.000 title claims abstract description 17
- 230000002159 abnormal effect Effects 0.000 title claims description 43
- 239000002773 nucleotide Substances 0.000 claims abstract description 23
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 23
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 230000001594 aberrant effect Effects 0.000 claims abstract description 3
- 210000000349 chromosome Anatomy 0.000 claims description 273
- 210000004027 cell Anatomy 0.000 claims description 190
- 108700039143 HMGA2 Proteins 0.000 claims description 108
- 108020004414 DNA Proteins 0.000 claims description 102
- 238000000034 method Methods 0.000 claims description 67
- 230000014509 gene expression Effects 0.000 claims description 63
- 208000003200 Adenoma Diseases 0.000 claims description 60
- 239000000523 sample Substances 0.000 claims description 57
- 206010024612 Lipoma Diseases 0.000 claims description 49
- 230000005856 abnormality Effects 0.000 claims description 48
- 230000005945 translocation Effects 0.000 claims description 46
- 201000010260 leiomyoma Diseases 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 238000009396 hybridization Methods 0.000 claims description 39
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 38
- 101150035390 mag gene Proteins 0.000 claims description 38
- 239000012634 fragment Substances 0.000 claims description 37
- 210000004881 tumor cell Anatomy 0.000 claims description 35
- 201000007954 uterine fibroid Diseases 0.000 claims description 32
- 239000002299 complementary DNA Substances 0.000 claims description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 19
- 210000004072 lung Anatomy 0.000 claims description 19
- 230000002062 proliferating effect Effects 0.000 claims description 19
- 238000003745 diagnosis Methods 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000002927 Hamartoma Diseases 0.000 claims description 14
- 210000000481 breast Anatomy 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 108020004999 messenger RNA Proteins 0.000 claims description 13
- 238000002105 Southern blotting Methods 0.000 claims description 12
- 208000032839 leukemia Diseases 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 11
- 238000011160 research Methods 0.000 claims description 11
- 108091008146 restriction endonucleases Proteins 0.000 claims description 11
- 238000003757 reverse transcription PCR Methods 0.000 claims description 11
- 230000007017 scission Effects 0.000 claims description 11
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 238000001574 biopsy Methods 0.000 claims description 10
- 238000002405 diagnostic procedure Methods 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 10
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 238000010171 animal model Methods 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 230000036210 malignancy Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 8
- 101150074251 lpp gene Proteins 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 208000016018 endometrial polyp Diseases 0.000 claims description 6
- 206010046811 uterine polyp Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 238000011065 in-situ storage Methods 0.000 claims description 5
- 229920002521 macromolecule Polymers 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims description 5
- 201000008968 osteosarcoma Diseases 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- 108020005544 Antisense RNA Proteins 0.000 claims description 4
- 239000003184 complementary RNA Substances 0.000 claims description 4
- 201000011066 hemangioma Diseases 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 208000025443 tumor of adipose tissue Diseases 0.000 claims description 4
- 208000037062 Polyps Diseases 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 210000004696 endometrium Anatomy 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102100035184 General transcription and DNA repair factor IIH helicase subunit XPD Human genes 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 102000004381 Complement C2 Human genes 0.000 claims 1
- 108090000955 Complement C2 Proteins 0.000 claims 1
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 101000800735 Mycolicibacterium fortuitum Putative 3-methyladenine DNA glycosylase Proteins 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 241000282577 Pan troglodytes Species 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 102000045222 parkin Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 125
- 102000049982 HMGA2 Human genes 0.000 description 78
- 238000004458 analytical method Methods 0.000 description 66
- 238000013507 mapping Methods 0.000 description 49
- 206010001233 Adenoma benign Diseases 0.000 description 42
- 238000002474 experimental method Methods 0.000 description 42
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 description 38
- 238000003752 polymerase chain reaction Methods 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 33
- 210000001519 tissue Anatomy 0.000 description 28
- 239000000047 product Substances 0.000 description 26
- 102000049983 HMGA1a Human genes 0.000 description 23
- 108700039142 HMGA1a Proteins 0.000 description 23
- 230000031864 metaphase Effects 0.000 description 23
- 230000002559 cytogenic effect Effects 0.000 description 20
- 230000002759 chromosomal effect Effects 0.000 description 17
- 239000002609 medium Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 15
- 238000012216 screening Methods 0.000 description 15
- 108700024394 Exon Proteins 0.000 description 14
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 description 14
- 230000003321 amplification Effects 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 14
- 108091008038 CHOP Proteins 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 239000003068 molecular probe Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000031404 Chromosome Aberrations Diseases 0.000 description 12
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 12
- 210000003917 human chromosome Anatomy 0.000 description 10
- 210000003079 salivary gland Anatomy 0.000 description 10
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 238000005520 cutting process Methods 0.000 description 9
- 206010024627 liposarcoma Diseases 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 description 8
- 230000004568 DNA-binding Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000008520 organization Effects 0.000 description 8
- 230000008707 rearrangement Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 101710101078 Proton-activated chloride channel Proteins 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 208000035970 Chromosome Breakpoints Diseases 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108091035539 telomere Proteins 0.000 description 6
- 102000055501 telomere Human genes 0.000 description 6
- 210000003411 telomere Anatomy 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 101150004167 HMG gene Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000004754 hybrid cell Anatomy 0.000 description 5
- 238000007901 in situ hybridization Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 208000025444 tumor of salivary gland Diseases 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000000258 minor salivary gland Anatomy 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 230000005748 tumor development Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 208000022752 well-differentiated liposarcoma Diseases 0.000 description 4
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108091029523 CpG island Proteins 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000006050 Hemangiopericytoma Diseases 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- AZRNEVJSOSKAOC-VPHBQDTQSA-N [[(2r,3s,5r)-5-[5-[(e)-3-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoylamino]prop-1-enyl]-2,4-dioxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(\C=C\CNC(=O)CCCCCNC(=O)CCCC[C@H]2[C@H]3NC(=O)N[C@H]3CS2)=C1 AZRNEVJSOSKAOC-VPHBQDTQSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000002230 centromere Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 230000008711 chromosomal rearrangement Effects 0.000 description 3
- 201000000292 clear cell sarcoma Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 208000004333 pleomorphic adenoma Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 210000001913 submandibular gland Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000005262 Chondroma Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 102000048470 Dixin Human genes 0.000 description 2
- 108700037673 Dixin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- 102000055207 HMGB1 Human genes 0.000 description 2
- 108700010013 HMGB1 Proteins 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000866795 Homo sapiens Non-histone chromosomal protein HMG-14 Proteins 0.000 description 2
- 101000584600 Homo sapiens Ras-related protein Rap-1b Proteins 0.000 description 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100031353 Non-histone chromosomal protein HMG-14 Human genes 0.000 description 2
- 208000033498 Non-syndromic pontocerebellar hypoplasia Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 2
- 102100030705 Ras-related protein Rap-1b Human genes 0.000 description 2
- 239000007976 Tris-NaCl-Tween buffer Substances 0.000 description 2
- 210000005221 acidic domain Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 208000012999 benign epithelial neoplasm Diseases 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000000754 myometrium Anatomy 0.000 description 2
- 208000009091 myxoma Diseases 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 208000004351 pontocerebellar hypoplasia Diseases 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- 101100178203 Arabidopsis thaliana HMGB3 gene Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 101150117569 BRL3 gene Proteins 0.000 description 1
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000012609 Cowden disease Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000021994 Diffuse astrocytoma Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- -1 EST01096 Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- HEVGGTGPGPKZHF-UHFFFAOYSA-N Epilaurene Natural products CC1C(=C)CCC1(C)C1=CC=C(C)C=C1 HEVGGTGPGPKZHF-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000874889 Euphilotes enoptes Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 101150082239 G gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 101150091750 HMG1 gene Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 102000055206 HMGN2 Human genes 0.000 description 1
- 108700010011 HMGN2 Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000614095 Homo sapiens Proton-activated chloride channel Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000002693 Multiple Abnormalities Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 206010073137 Myxoid liposarcoma Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 101150005926 Pc gene Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000039796 Pythia Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000035582 Rare soft tissue tumor Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000231739 Rutilus rutilus Species 0.000 description 1
- 101150096783 STS gene Proteins 0.000 description 1
- 101100315733 Schizosaccharomyces pombe (strain 972 / ATCC 24843) uap2 gene Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710200257 Transcription factor atf-2 Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- GVBNSPFBYXGREE-CXWAGAITSA-N Visnadin Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)[C@H](C)CC)C(C)(C)O1 GVBNSPFBYXGREE-CXWAGAITSA-N 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- FMYKJLXRRQTBOR-BZSNNMDCSA-N acetylleucyl-leucyl-norleucinal Chemical compound CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O FMYKJLXRRQTBOR-BZSNNMDCSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 201000010878 atypical lipomatous tumor Diseases 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000012080 benign lipomatous neoplasm Diseases 0.000 description 1
- 201000004444 benign mesenchymoma Diseases 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000016160 chondroid hamartoma Diseases 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000017772 hamartoma of lung Diseases 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000002415 kinetochore Anatomy 0.000 description 1
- 101150048787 lig gene Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000001853 pulsed-field electrophoresis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229940116238 revex Drugs 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000004325 uterine smooth muscle cell Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
- 108010088577 zinc-binding protein Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.高速移動群タンパク質遺伝子またはLIMタンパク質遺伝子(これらの修 飾体を含む)の成員の一つの鎖の一つのヌクレオチド配列を有する多重腫瘍異常 生長(MAG)遺伝子。 2.図7に示されたHMGI−C遺伝子のヌクレオチド配列またはその相補的 鎖(両鎖の修飾体または伸長体を含む)を基本的に有する、請求項1の多重腫瘍 異常生長因子。 3.図5に示されたLPP遺伝子のヌクレオチド配列またはその相補的鎖(両 鎖の修飾体または伸長体を含む)を基本的に有する、請求項1の多重腫瘍異常生 長因子。 4.ヒトまたは動物における非生理的増殖現象の処置のための適切な発現調節 の化合物または技術を設計するための開始点として使用する、請求項1、2また は3の多重腫瘍異常生長因子。 5.非生理的増殖能を有する細胞を野生型細胞と比較して(臨床的に/医学的 に)診断するための適切なヌクレオチド・プローブを設計するための開始点とし て使用する、請求項1、2または3の多重腫瘍異常生長因子。 6.非生理的増殖能を有する細胞を野生型細胞と比較して(臨床的に/医学的 に)診断するための適切な抗体を製造するための開始点として使用する、請求項 1、2または3の多重腫瘍異常生長因子。 7.MAG遺伝子の誘導体がセンスおよびアンチセンスcDNAまたはそのフ ラグメント、該遺伝子の転写物またはその実際に用い得るフラグメント、アンチ センスRNA、該遺伝子のフラグメントまたはその相補的鎖、該遺伝子よりコー ドされたタンパク質またはそのフラグメント、該遺伝子、該cDNA、該転写物 、該タンパク質またはそれらのフラグメントに対する抗体および抗体フラグメン トからなる群より選ばれ、診断および治療的組成物の調製に使用される、請求項 1、2または3のMAG遺伝子の、またはその直接の近隣の誘導体。 8.下記の段階 a)請求項1または2のMAG遺伝子のヌクレオチド配列から得られる情報に基 づく1セットのヌクレオチド・プローブを設計する(該プローブの一つは、野生 型遺伝子の対応領域として、同じ座に実質的に位置する異常遺伝子の領域にハイ ブリダイズ可能であり、他のプローブは、野生型遺伝子の対応領域より異なる座 に位置する異常遺伝子の領域にハイブリダイズ可能である)、 b)非生理的増殖能を有する1以上の中間層または間層染色体または細胞をプロ ーブと共にハイブリダイズ条件でインキュベートする、 c)プローブと遺伝子とのハイブリダイゼイションを可視化する、 の少なくともいくつかを含む、非生理的増殖能を有する細胞を診断するためのイ ンサイトゥ診断法。 9.下記の段階 a)診断すべき細胞の生検を採取する、 b)それより適当なMAG遺伝子関連マクロ分子を単離する、 c)得たマクロ分子を望ましくは同じ個体からの野生型参考分子と比較すること により分析する、 の少なくともいくつかを含む、非生理的増殖能を有する細胞を診断する方法。 10.下記の段階 a)診断すべき細胞の生検を採取する、 b)その全RNAを抽出する、 c)全RNA中のmRNA種の少なくとも一つの第一鎖cDNA(cDNAは適 当なティルを有する)を調製する、 d)MAG遺伝子特異cDNAを増幅するために、MAG遺伝子特異プライマー およびティル−特異および/または相手特異/整列プライマーを用いてPCRお よび/またはRT−PCRを行う、 e)バンドのパターンを得るために、ゲル上でPCR産物を分離する、 f)異常バンドの存在を、望ましくは同じ個体からの野生型バンドとの比較によ り調べる、 の少なくともいくつかを含む、請求項9の方法。 11.下記の段階 a)診断すべき細胞の生検を採取する、 b)それから全タンパク質を単離する、 c)基本的に個々のバンドを得るためにゲル上で全タンパク質を分離し、そして 選択的にバンドをウエスタン・ブロットに移行する、 d)得たバンドを、MAG遺伝子の残り部分によりコードされるタンパク質の部 分に対する、およびMAG遺伝子の置換部分によりコードされたタンパク質の部 分に対する抗体と共にハイブリダイズする、 e)抗原−抗体反応を可視化し、望ましくは同じ個体からの野生型タンパク質よ りのバンドとの比較で異常バンドの存在を確認する、 の少なくともいくつかを含む、請求項9の方法。 12.下記の段階 a)診断すべき細胞の生検を採取する、 b)それから全DNAを単離する、 c)DNAを1以上のいわゆる“希切断”制限酵素で消化する、 d)分離パターンを得るために、調製した消化物を分離する、 e)選択的に分離パターンをサザンブロットに移行する、 f)ゲル中またはブロット上の分離パターンを1以上の情報プローブと共にハイ ブリダイズ条件でハイブリダイズする、 g)ハイブリダイゼンションを可視化し、望ましくは同じ個体からの野生型タン パク質よりのバンドとの比較で異常バンドの存在を確認する、 の少なくともいくつかを含む、請求項9の方法。 13.下記の段階 a)診断すべき細胞の生検を採取する、 b)それからmRNAを抽出する、 c)MAG遺伝子から誘導されるmRNAの存在または(比較の)量を確認する、 d)段階c)の結果を望ましくは同じ個体からの野生細胞での同様の実験結果と 比較する、 の少なくともいくつかを含む、請求項9の方法。 14.非生理的増殖能を有する細胞が間葉腫瘍過誤腫(例えば乳房および肺) 、脂肪性組織腫瘍(例えば脂肪腫)、多形態性唾液腺腫、子宮平滑筋腫、血管筋 腫、肺の腺維腫、子宮内膜のポリープ、動脈硬化性プラークおよび他の良性腫瘍 、さらに肉腫(例えば横紋筋肉腫、骨肉腫)および癌腫(例えば乳房、肺、皮膚 、甲状線の)などの種々の悪性腫瘍、さらに白血病およびリンパ腫のような血液 学的悪性腫瘍からなる群より選択される、請求項8−9のいずれかの方法。 15.非生理的増殖能を有する細胞が関与する疾患を該遺伝子の発現を調節す ることにより処置するのに用いる、請求項1、2または3のMAG遺伝子のアン チセンス分子。 16.非生理的増殖能を有する細胞が関与する疾患の処置に用いる、請求項1 、2または3のMAG遺伝子の阻害剤または促進剤(リボチームを含む)などの 発現調節剤。 17.非生理的増殖能を有する細胞が関与する疾患の処置に用いる、請求項1 、2または3のMAG遺伝子のmRNA分子に相補的なアンチセンスRNA分子 および/またはMAG遺伝子の遺伝子産物に対する抗体。 18.標識ヌクレオチド・プローブの適当なセットを含む、請求項8の方法を 実施するための診断キット。 19.標識ヌクレオチド・プローブの適当なセットを含む、請求項10の方法 を実施するための診断キット。 20.標識MAG遺伝子特異およびティル特異PCRプライマーの適当なセッ トを含む、請求項11の方法を実施するための診断キット。 21.標識プローブの適当なセットおよび適当な希切断制限酵素を含む、請求 項11の方法を実施するための診断キット。 22.請求項7の誘導体を1以上および/または請求項16の発現調節剤を1 以上含む、非生理的増殖能を有する細胞におけるMAG遺伝子発現レベルを低下 せしめるための医薬組成物。 23.非生理的増殖能を有する細胞が間葉腫瘍過誤腫(例えば乳房および肺) 、 脂肪性組織腫瘍(例えば脂肪腫)、多形態性唾液腺腫、子宮平滑筋腫、血管筋腫 、肺の腺維腫、子宮内膜のポリープ、動脈硬化性プラークおよび他の良性腫瘍、 さらに肉腫(例えば横紋筋肉腫、骨肉腫)および癌腫(例えば乳房、肺、皮膚、 甲状線の)などの種々の悪性腫瘍、さらに白血病およびリンパ腫のような血液学 的悪性腫瘍からなる群より選択される、請求項22の医薬組成物。 24.非生理的増殖能を有する細胞に関連する疾患または障害の診断または処 置のための診断キットまたは医薬組成物の製造のための請求項7の誘導体の使用 。 25.非生理的増殖能を有する細胞に関連する疾患または障害の診断または処 置のための診断キットまたは医薬組成物の製造のための請求項16の発現調節剤 の使用。 26.非生理的増殖能を有する細胞が間葉腫瘍過誤腫(例えば乳房および肺) 、脂肪性組織腫瘍(例えば脂肪腫)、多形態性唾液腺腫、子宮平滑筋腫、血管筋 腫、肺の腺維腫、子宮内膜のポリープ、動脈硬化性プラークおよび他の良性腫瘍 、さらに肉腫(例えば横紋筋肉腫、骨肉腫)および癌腫(例えば乳房、肺、皮膚 、甲状線の)などの種々の悪性腫瘍、さらに白血病およびリンパ腫のような血液 学的悪性腫瘍からなる群より選択される、請求項24および25の使用。 27.分子トゥール(プローブ、プライマーなど)を設計するためのMAGタ ンパク質の少なくとも一部分を用いて腫瘍細胞における融合遺伝子、融合転写物 または融合タンパク質の存在に基づく他のMAG遺伝子を単離するための方法。 28.請求項27の方法により得られるMAG遺伝子。 29.診断的または治療的方法に使用するための請求項28のMAG遺伝子。 30.動物がそのゲノムにMAG遺伝子を所有する形質転換動物である、非生 理的増殖能を有する細胞に関連する疾患または障害の処置における化合物または 組成物の有用性検定のための動物モデル。 31.MAG遺伝子が、遺伝子の残り部分およびその転座相手の置換部分の融 合産物などの異常MAG遺伝子である、請求項30の動物モデル。 32.MAG遺伝子が非生理的発現レベルを示す、請求項30の動物モデル。 33.動物がその細胞の、少なくとも部分のゲノムにおいて請求項1、2また は3のMAG遺伝子に影響を及ぼす特異的遺伝子異常を所有し、その異常が胚胎 幹細胞における相同組換えを経由して誘導される、非生理的増殖能を有する細胞 に関連する疾患または障害の処置における化合物または組成物の有用性検定のた めの動物モデル。 34.動物が哺乳動物、特にマウス、ラット、イヌ、ブタまたはチンパンジー のような高等霊長動物である、請求項30−33のいずれかの動物モデル。 35.詳細な説明および図面に開示したポリ−またはオリゴヌクレオチド・プ ローブおよびプライマー。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95200390 | 1995-02-17 | ||
NL95201951.1 | 1995-07-14 | ||
EP95201951A EP0727487A1 (en) | 1995-02-17 | 1995-07-14 | Multiple-tumor aberrant growth genes |
NL95200390.3 | 1995-07-14 | ||
PCT/EP1996/000716 WO1996025493A1 (en) | 1995-02-17 | 1996-02-19 | Multiple-tumor aberrant growth genes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006262093A Division JP2007082549A (ja) | 1995-02-17 | 2006-09-27 | 多重腫瘍異常生長遺伝子 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11500614A true JPH11500614A (ja) | 1999-01-19 |
Family
ID=8220025
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8524678A Withdrawn JPH11500614A (ja) | 1995-02-17 | 1996-02-19 | 多重腫瘍異常生長遺伝子 |
JP2006262093A Withdrawn JP2007082549A (ja) | 1995-02-17 | 2006-09-27 | 多重腫瘍異常生長遺伝子 |
JP2007290671A Pending JP2008099698A (ja) | 1995-02-17 | 2007-11-08 | 多重腫瘍異常生長遺伝子 |
JP2009173847A Pending JP2009254378A (ja) | 1995-02-17 | 2009-07-27 | 多重腫瘍異常生長遺伝子 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006262093A Withdrawn JP2007082549A (ja) | 1995-02-17 | 2006-09-27 | 多重腫瘍異常生長遺伝子 |
JP2007290671A Pending JP2008099698A (ja) | 1995-02-17 | 2007-11-08 | 多重腫瘍異常生長遺伝子 |
JP2009173847A Pending JP2009254378A (ja) | 1995-02-17 | 2009-07-27 | 多重腫瘍異常生長遺伝子 |
Country Status (14)
Country | Link |
---|---|
US (3) | US6544784B1 (ja) |
EP (3) | EP0727487A1 (ja) |
JP (4) | JPH11500614A (ja) |
KR (1) | KR19980702276A (ja) |
AT (1) | ATE338114T1 (ja) |
AU (1) | AU4879096A (ja) |
CA (1) | CA2213237A1 (ja) |
CZ (1) | CZ247597A3 (ja) |
DE (2) | DE69636495T2 (ja) |
FI (1) | FI973354A (ja) |
HU (1) | HUP9800028A3 (ja) |
NO (1) | NO973685L (ja) |
PL (1) | PL321831A1 (ja) |
WO (1) | WO1996025493A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009219462A (ja) * | 2008-03-18 | 2009-10-01 | Jokoh Co Ltd | 悪性腫瘍の予想、診断のための方法および組成物 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19548122A1 (de) * | 1995-12-21 | 1997-06-26 | Joern Prof Dr Bullerdiek | Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben |
US6323329B1 (en) | 1995-12-21 | 2001-11-27 | Jorn Bullerdiek | Nucleic acid sequences of genes encoding high mobility group proteins |
US6720472B2 (en) | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
US6171779B1 (en) | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
CA2259635A1 (en) * | 1997-05-07 | 1998-11-12 | Kiran Chada | Hmgi proteins in tumors and obesity |
EP0878552A1 (en) * | 1997-05-13 | 1998-11-18 | Erasmus Universiteit Rotterdam | Molecular detection of chromosome aberrations |
US7923250B2 (en) | 1997-07-30 | 2011-04-12 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein in non-osseous cells |
DE69840361D1 (de) | 1997-07-30 | 2009-01-29 | Univ Emory | Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme |
EP1078098A1 (en) * | 1998-05-04 | 2001-02-28 | Dako A/S | Method and probes for the detection of chromosome aberrations |
US6601371B1 (en) | 1998-05-05 | 2003-08-05 | Erwin Fertig | Packaging machine |
IT1299583B1 (it) * | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
DE19904514A1 (de) * | 1999-02-04 | 2000-08-10 | Joern Bullerdiek | Mittel zur Prävention und/oder Behandlung von Leiomyomen |
US7151082B2 (en) | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
JP2004538452A (ja) * | 2001-06-27 | 2004-12-24 | ザ ウォルター アンド イライザ ホール インスティチュート オブ メディカル リサーチ | 診断法と診断薬 |
AU2002358771B2 (en) * | 2001-12-19 | 2009-04-23 | Alcedo Biotech Gmbh | Use of HMGB proteins and nucleic acids that code therefor |
WO2003087317A2 (en) * | 2002-04-05 | 2003-10-23 | Cyternex, Inc. | Methods for targeting quadruplex dna |
US20030219742A1 (en) * | 2002-03-29 | 2003-11-27 | Sanjay Bhanot | Antisense modulation of HMGI-C expression |
NZ538782A (en) * | 2002-08-20 | 2008-05-30 | Univ Arizona | Methods for regulating transcription by targeting quadruplex DNA |
US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
EP1668035A2 (en) | 2003-09-11 | 2006-06-14 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
US8415315B2 (en) | 2004-05-06 | 2013-04-09 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for inhibiting the proliferation of cancer cells |
US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
KR20070090890A (ko) | 2004-10-22 | 2007-09-06 | 메디뮨 인코포레이티드 | Hmgb1에 대한 고 친화성 항체 및 이의 사용 방법 |
WO2007076200A2 (en) | 2005-11-28 | 2007-07-05 | Medimmune, Inc. | Antagonists of hmgb1 and/or rage and methods of use thereof |
EP2123297A4 (en) | 2007-02-15 | 2011-10-12 | Univ Kumamoto | THERAPEUTIC AGENT COMPRISING AN ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO HMGB-1 AS ACTIVE INGREDIENT |
US20100297649A1 (en) * | 2009-04-22 | 2010-11-25 | Oliveira Andre M | Methods and materials for detecting gene amplification |
EP2764118A1 (en) | 2011-10-05 | 2014-08-13 | University of Bremen | Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases |
US20180127831A1 (en) * | 2015-05-21 | 2018-05-10 | Université de Montréal | Prognostic markers of acute myeloid leukemia survival |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62166897A (ja) * | 1986-01-20 | 1987-07-23 | Toyo Soda Mfg Co Ltd | 核内非ヒストン蛋白質に対するモノクロ−ナル抗体 |
EP0498827B1 (en) * | 1989-11-02 | 2001-08-01 | DictyTech Pty Limited | Improved plasmid vectors for cellular slime moulds of the genus dictyostelium |
US5756307A (en) * | 1991-09-20 | 1998-05-26 | The United States Of America As Represented By The Department Of Health And Human Services | Sequence of human dopamine transporter cDNA |
US6171779B1 (en) * | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
-
1995
- 1995-07-14 EP EP95201951A patent/EP0727487A1/en not_active Withdrawn
-
1996
- 1996-02-19 PL PL96321831A patent/PL321831A1/xx unknown
- 1996-02-19 CZ CZ972475A patent/CZ247597A3/cs unknown
- 1996-02-19 JP JP8524678A patent/JPH11500614A/ja not_active Withdrawn
- 1996-02-19 KR KR1019970705673A patent/KR19980702276A/ko not_active Application Discontinuation
- 1996-02-19 US US08/894,454 patent/US6544784B1/en not_active Expired - Fee Related
- 1996-02-19 DE DE69636495T patent/DE69636495T2/de not_active Expired - Fee Related
- 1996-02-19 EP EP06076468.5A patent/EP1762619B1/en not_active Expired - Lifetime
- 1996-02-19 HU HU9800028A patent/HUP9800028A3/hu unknown
- 1996-02-19 WO PCT/EP1996/000716 patent/WO1996025493A1/en active IP Right Grant
- 1996-02-19 AT AT96904836T patent/ATE338114T1/de not_active IP Right Cessation
- 1996-02-19 CA CA002213237A patent/CA2213237A1/en not_active Abandoned
- 1996-02-19 EP EP96904836A patent/EP0811061B2/en not_active Expired - Lifetime
- 1996-02-19 DE DE0811061T patent/DE811061T1/de active Pending
- 1996-02-19 AU AU48790/96A patent/AU4879096A/en not_active Abandoned
-
1997
- 1997-08-11 NO NO973685A patent/NO973685L/no not_active Application Discontinuation
- 1997-08-15 FI FI973354A patent/FI973354A/fi unknown
-
2003
- 2003-01-28 US US10/352,615 patent/US20030190285A1/en not_active Abandoned
-
2006
- 2006-09-27 JP JP2006262093A patent/JP2007082549A/ja not_active Withdrawn
-
2007
- 2007-05-25 US US11/807,330 patent/US20110318834A1/en not_active Abandoned
- 2007-11-08 JP JP2007290671A patent/JP2008099698A/ja active Pending
-
2009
- 2009-07-27 JP JP2009173847A patent/JP2009254378A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009219462A (ja) * | 2008-03-18 | 2009-10-01 | Jokoh Co Ltd | 悪性腫瘍の予想、診断のための方法および組成物 |
Also Published As
Publication number | Publication date |
---|---|
NO973685D0 (no) | 1997-08-11 |
ATE338114T1 (de) | 2006-09-15 |
FI973354A0 (fi) | 1997-08-15 |
FI973354A (fi) | 1997-10-16 |
DE811061T1 (de) | 2002-10-17 |
EP1762619A2 (en) | 2007-03-14 |
CZ247597A3 (cs) | 1998-07-15 |
KR19980702276A (ko) | 1998-07-15 |
PL321831A1 (en) | 1997-12-22 |
EP0811061A1 (en) | 1997-12-10 |
US6544784B1 (en) | 2003-04-08 |
EP1762619A3 (en) | 2007-05-09 |
EP1762619B1 (en) | 2013-06-26 |
EP0727487A1 (en) | 1996-08-21 |
WO1996025493A1 (en) | 1996-08-22 |
NO973685L (no) | 1997-10-17 |
EP0811061B2 (en) | 2010-07-21 |
DE69636495D1 (de) | 2006-10-12 |
AU4879096A (en) | 1996-09-04 |
HUP9800028A2 (hu) | 1998-04-28 |
JP2009254378A (ja) | 2009-11-05 |
JP2008099698A (ja) | 2008-05-01 |
JP2007082549A (ja) | 2007-04-05 |
DE69636495T2 (de) | 2007-05-24 |
US20030190285A1 (en) | 2003-10-09 |
EP0811061B1 (en) | 2006-08-30 |
HUP9800028A3 (en) | 2001-02-28 |
CA2213237A1 (en) | 1996-08-22 |
US20110318834A1 (en) | 2011-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11500614A (ja) | 多重腫瘍異常生長遺伝子 | |
Sirotkin et al. | Identification of a New Human Catenin Gene Family Member (ARVCF) from the Region Deleted in Velo–Cardio–Facial Syndrome | |
AU686004B2 (en) | In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene | |
JP2000500985A (ja) | 第13染色体連鎖−乳癌感受性遺伝子 | |
JPH10507343A (ja) | 網膜芽細胞腫タンパク質相互作用性ジンクフィンガータンパク質 | |
JPH03505675A (ja) | 新生表現型の抑制を制御する産生体及び方法 | |
KR20010085315A (ko) | 부정맥과 관련된 인간 minK 유전자 돌연변이 | |
JPH11504803A (ja) | ヒト転移サプレッサー遺伝子kai1に由来する試薬を使用する診断方法及び遺伝子療法 | |
JP2002511749A (ja) | 9q32−33での腫瘍サプレッサー遺伝子DBCCR1 | |
JP2000507823A (ja) | フォンヒッペル・リンドウ(vhl)病遺伝子の部分的イントロン配列及び疾病の診断におけるその使用 | |
JP2001501445A (ja) | KVLQT1をコードする長QT症候群遺伝子およびそのminKとの関連 | |
PT613945E (pt) | Gene merlin supressor de tumores e suas utilizacoes | |
EP0825198A1 (en) | Plag gene family and tumorigenesis | |
US20030054446A1 (en) | Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379 | |
US6177410B1 (en) | Therapeutic methods for prostate cancer | |
US5858771A (en) | Products and methods for controlling the suppression of the neoplastic phenotype | |
US7462447B2 (en) | Methods for evaluating susceptibility to a bone homeostasis disorder | |
JP2004516813A (ja) | 関連腫瘍マーカー | |
AU759752B2 (en) | Multiple-tumor aberrant growth genes | |
JPH10127296A (ja) | Ext2遺伝子 | |
US7060688B2 (en) | Products and methods for controlling the suppression of the neoplastic phenotype | |
JP2000512133A (ja) | 多発性骨髄腫で変化した遺伝子の同定 | |
JP2002504805A (ja) | 基底細胞癌腫瘍抑制遺伝子 | |
JP2005505232A (ja) | 腸タンパク質 | |
AU2007200451A1 (en) | Multiple-tumor aberrant growth genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051129 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060424 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060530 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20061127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061124 |